Sponsored by
This is an interesting drug combination strategy aimed at enhancing standard of care for glioblastoma (GBM) by targeting multiple pathways involved in tumor growth. Like the earlier CUSP9v3 protocol, AVRO proposed repurposing well-tolerated, FDA-approved non-oncology drugs based on preclinical evidence of GBM inhibition. The article mentions potential interaction between levetiracetam (Keppra) and vortioxetine/olanzapine and thus mentions lacosamide (Vimpat) may be a preferable seizure prophylaxis for patients under the AVRO regime.